MONOGENETIC DISEASE THERAPY MARKET SIZE, SHARE, GROWTH REPORT 2025

  • Product Code:
    RP-ID-10220969
  • Published Date:
    17 Jul 2021
  • Region:
    Global
  • Pages:
    180
  • Category:
    Healthcare & Pharmaceuticals
  • Publisher:
    Pub-ID-41

Impact Analysis on the Growth of Market

Activating Probable Propositions Amidst COVID-19 Crisis

With things going haywire, we analyze key points to make sure that the businesses around the globe are completely prepared to tackle potential implications caused by COVID-19. Be it protecting employees, customers or the overall business operations, we ensure that the employers take the right decisions, make strategic investments and maintain a healthy work culture along with taking probable measures to minimize the financial loss. Know More

The Research Report is Updated with 2020 Base Year, 2021 Estimated year and Forecast till 2030 with Market Insights.


With the dip in global production, the GDP has contracted in 2020 and impacted the market across the world. Upon placing a Sample Request, you will receive an updated report with 2020 as base year, 2021 as estimated year and forecast to 2030. This will have market drivers, recovery rate in the market, insights and competitive analysis.



Market Overview:

Monogenetic Disease Therapy Market: Introduction

Monogenetic diseases result from the mutation or change in the DNA sequence of one gene. A mutated gene hinders the normal functioning of the protein present in its composition and hence results in various types of monogenetic disorders such as cystic fibrosis, sickle cell disease, Gaucher disease, SCID and others. The monogenetic disease therapy market is expected to grow during the forecast period, due to a rise in the incidence of monogenetic diseases, coupled with advancement in treatment technologies.

Market Dynamics:

The monogenetic disease therapy market is expected to grow during the forecast period, due to the rising prevalence of monogenetic diseases globally. According to the World Health Organization (WHO), the global prevalence of all monogenetic diseases at birth is approximately 10/1000. Increased research activities and clinical trials on monogenic diseases and its therapeutic treatments are further anticipated to drive the monogenetic diseases therapy market. According to NCBI, monogenetic diseases were the second most popular indication of gene therapies after cancer, accounted for 10% of the total gene therapy trials conducted between 1989 and 2015. Other driving factors for the growth of monogenetic disease therapy market include rising awareness towards genetic diseases, coupled with the presence of key healthcare market players such as Sanofi, Bayer AG, Pfizer Inc., and others who are determined to develop innovative therapies, advanced bio-instruments, and vaccines to treat monogenetic diseases.

However, high therapy cost and lower commercial success rates of treatments like gene therapy can restrain the growth of global monogenetic disease therapy market.

By Inheritance Pattern

On the basis of inheritance pattern, autosomal monogenetic diseases therapy market is expected to grow at a faster pace, due to rise in a number of autosomal monogenetic diseases like Cystic fibrosis (a most common type of monogenetic disease), Tay Sachs disease and Sickle cell anemia. According to the European Lung White Book, one in 25 people of European descent carries one mutant allele of CFTR, and one person among 2000-3000 people is affected by cystic fibrosis. Chromosomal disease therapy is also expected to grow during the forecast period, owing to the rising incidence of hemophilia, hunter disease, and others. Haemophilia is estimated to be afflicted in 1 in 10,000 people globally.

By Therapy Type

Pharmacological and surgical therapies for treating monogenetic diseases are predicted to dominate the global market, due to their higher preference among patients. For instance, in February 2018, the U.S. FDA approved a combination of ivacaftor and tezacaftor, developed by Vertex Pharmaceutical, to treat cystic fibrosis. Gene therapy is another therapy segment which is expected to witness a rapid growth over the forecast period, owing to its efficiency in the treatment of monogenetic diseases like CF and SCID. For instance, Glybera, which is the first clinically approved gene therapy in the European Union, uses an adeno-associated virus (AAV) vector drug for correction of lipoprotein lipase deficiency and to correct cystic fibrosis, it uses repeated nebulization of liposomes encoding the cystic fibrosis transmembrane conductance regulator (CFTR).

Competitive Landscape

Key market players operating in global monogenetic disease therapy market include Abbott Laboratories, BAG Healthcare Gmbh, Novartis, Pfizer Inc., Vertex Pharmaceuticals, Bristol-Myers Squibb, F. Hoffmann-La Roche Limited, Bayer AG, Grifols S.A, Bluebird Bio, UniQure, and Sanofi S.A.

Market players, clinical research organizations and hospitals are focusing on collaborations to develop and commercialize therapies for the treatment of monogenetic diseases. For instance, in August 2018, Mustang Bio, a U.S. based pharmaceutical firm entered into an exclusive license agreement with St. Jude Children’s Research Hospital to develop the ex-vivo lentiviral gene therapy for X-linked SCID (commonly known as Bubble Boy Disease) treatment. Through this merger, Mustang Bio aims to expand their pipeline into gene therapy for patients with X-SCID.


Geography Analysis:


The report further discusses the market opportunity, compound annual growth rate (CAGR) growth rate, competition, new technology innovations, market players analysis, government guidelines, export and import (EXIM) analysis, historical revenues, future forecasts etc. in the following regions and/or countries:

  • North America (U.S. & Canada) Market Size, Y-O-Y Growth, Market Players Analysis & Opportunity Outlook
  • Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market Size, Y-O-Y Growth & Market Players Analysis & Opportunity Outlook
  • Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC(Finland, Sweden, Norway, Denmark), Ireland, Switzerland, Austria, Poland, Turkey, Russia, Rest of Europe), Poland, Turkey, Russia, Rest of Europe) Market Size, Y-O-Y Growth Market Players Analys  & Opportunity Outlook
  • Asia-Pacific (China, India, Japan, South Korea, Singapore, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market Size, Y-O-Y Growth & Market Players Analysis & Opportunity Outlook
  • Middle East and Africa  (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market Size, Y-O-Y Growth Market Players Analysis & Opportunity Outlook

.

Please enter your personal details below
*
I want to buy this report
I am willing to know the scope of research
I have customized query over this report
Please enter your personal details below
*
I want to buy this report
I am willing to know the scope of research
I have customized query over this report

Related Reports